📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-07-24 18:29
477 analysed today
FollowTelegram
477
Today
149,878
All-time analysed
42,959
Positive
6,669
Negative
91,543
Neutral
8,639
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
19 announcements match the current filters (relevance ≥ 5).
₹10 Dividend Declared; AGM Set for Aug 20, 2026 with Key Management Appointments
Venus Remedies has scheduled its 37th Annual General Meeting (AGM) for August 20, 2026, to approve a final dividend of ₹10 per share (100% of face value). The record date for dividend eligibility is August 7, 2026. The company is also seeking shareholder approval for the appointment of Mr. Saransh Chaudhary as Executive Director for a five-year term at an annual salary of ₹93 Lacs. This follows a strong financial year where TTM PAT reached ₹103 Cr, a significant increase from ₹45.33 Cr in FY25.
Confidence: HIGH
What changedThe company has formalized its dividend payout for FY26 and is restructuring its board with new executive and independent director appointments.
Why it mattersThe ₹10 dividend reflects the company's improved profitability (TTM PAT up ~127% YoY), while the management appointments ensure leadership continuity for the next five-year cycle.
Dividend per share: ₹10Dividend Yield (approx): 0.6%Proposed ED Salary: ₹93.00 Lacs p.a.Record Date: August 7, 2026TTM PAT: ₹103 Cr
📅 Short termThe stock may see mild positive interest leading up to the August 7 record date for the ₹10 dividend.
📈 Long termThe company's shift toward IP-led formulations and AMR licensing milestones remains the primary structural driver beyond routine AGM proceedings.
⚠ Risk flags
- Management remuneration includes a provision for up to 20% annual increments.
Key Highlights
Final dividend of ₹10 per equity share (100% of face value) recommended for FY 2025-26.
Record date for dividend eligibility set for August 7, 2026, with the AGM on August 20, 2026.
Appointment of Mr. Saransh Chaudhary as Executive Director for 5 years at a salary of ₹93.00 Lacs per annum.
Proposed annual increment for the new Executive Director capped at 20% starting January 1st each year.
Ratification of Cost Auditor remuneration at ₹1,10,000 for the financial year 2026-27.
👀 What to Watch
Investors should note the August 7 record date for dividend eligibility and monitor the AGM for updates on the 'Global Venus Fulfilment Centre' expansion and VRP-034 commercialization progress.
Venus Remedies Q1 FY27 PAT Jumps 118% to ₹25.5 Cr; MOA Revised for Business Alignment
Venus Remedies reported a strong start to FY27 with standalone revenue growing 30.4% YoY to ₹178.80 cr. Net profit surged 118.2% YoY to ₹25.53 cr, with EPS rising to ₹19.40 from ₹8.75 in the year-ago quarter. The board also approved revisions to the Memorandum of Association (MOA) to align with the Companies Act 2013 and accommodate 'proposed business activities'. However, auditors highlighted ₹28.59 cr in pending share allotments for the German subsidiary, which is currently facing financial challenges and undergoing restructuring.
Confidence: HIGH
What changedThe company reported a significant jump in quarterly profitability and updated its constitutional documents (MOA/AOA) to align with current and future business objectives.
Why it mattersThe strong earnings growth suggests improved traction in the company's core pharmaceutical formulations. The MOA update provides the legal framework for potential diversification or expansion into new business segments.
Q1 FY27 Revenue: ₹178.80 crQ1 FY27 Net Profit: ₹25.53 crYoY Profit Growth: 118.2%German Subsidiary Investment: ₹28.59 crQ1 EBITDA Margin: 21.9%
📅 Short termThe stock is likely to react positively to the strong earnings beat and significant EPS growth in the immediate term.
📈 Long termLong-term value depends on the successful commercialization of IP-led research products like VRP-034 and the resolution of financial challenges in the European operations.
⚠ Risk flags
- Financial challenges in German subsidiary Venus Pharma GmbH
- Pending share allotment of ₹28.59 cr in subsidiary
- High dependence on export markets and exchange rate volatility
Key Highlights
Standalone Revenue from Operations grew 30.4% YoY to ₹178.80 cr in Q1 FY27.
Net Profit increased by 118.2% YoY to ₹25.53 cr, up from ₹11.70 cr in Q1 FY26.
EBITDA for the quarter stood at ₹39.11 cr, representing a margin of 21.9% compared to 15.1% in the previous year.
Outstanding share application money of ₹28.59 cr in German subsidiary Venus Pharma GmbH remains pending allotment.
Research & Development expenses for the quarter were ₹4.23 cr, approximately 2.4% of revenue.
👀 What to Watch
Investors should monitor the operational turnaround of the European subsidiaries and the specific 'proposed business activities' hinted at in the MOA revision. The sharp margin expansion in Q1 warrants a check on whether this is sustainable or driven by a one-off product mix.
Venus Remedies Q1 Net Profit Jumps 118% YoY to ₹25.53 Cr; Revenue Up 30%
Venus Remedies reported a strong start to FY27 with standalone revenue growing 30.4% YoY to ₹178.80 Cr. Net profit surged 118.2% YoY to ₹25.53 Cr, driven by significant operational leverage as EBITDA margins expanded from 15.1% to 21.9%. The board also approved updating the Memorandum of Association to include CDMO and CRO activities, signaling a strategic shift. However, auditors highlighted financial challenges at the German subsidiary, where ₹28.60 Cr in share application money remains pending allotment.
Confidence: HIGH
What changedThe company delivered a sharp increase in profitability and margins for Q1 FY27 and formally expanded its business scope to include contract manufacturing and research services.
Why it mattersThe margin expansion from 15.1% to 21.9% suggests improved pricing power or a better product mix, while the MOA update allows the company to diversify into higher-margin service-based pharmaceutical models.
Revenue (Q1 FY27): ₹178.80 CrNet Profit (Q1 FY27): ₹25.53 CrEBITDA Margin: 21.9%German Subsidiary Exposure: ₹28.60 CrRevenue vs TTM Revenue: 23.4%
📅 Short termThe stock is likely to react positively to the substantial YoY growth in both top-line and bottom-line figures.
📈 Long termThe structural shift towards IP-led formulations and CDMO services could re-rate the business if the German subsidiary's financial stress is successfully managed.
⚠ Risk flags
- Financial challenges in the German subsidiary (Venus Pharma GmbH)
- Pending share allotment of ₹28.60 Cr in subsidiary
- Export revenue sensitivity to exchange rate volatility
Key Highlights
Standalone Revenue from Operations increased 30.4% YoY to ₹178.80 Cr from ₹137.13 Cr.
Net Profit grew by 118.2% YoY to ₹25.53 Cr compared to ₹11.70 Cr in the same quarter last year.
EBITDA rose 89.3% YoY to ₹39.11 Cr, reflecting improved manufacturing and administrative efficiencies.
R&D expenses for the quarter stood at ₹4.23 Cr, approximately 2.3% of total income.
Auditor flagged ₹28.60 Cr (approx.) in outstanding share application money for the German subsidiary which is facing financial challenges.
👀 What to Watch
Monitor the execution of the European restructuring plan and the timeline for the commencement of new CDMO/CRO service lines as per the revised MOA.
Venus Remedies Secures DSIR Renewal for In-House R&D Unit VMRC
Venus Remedies has successfully renewed its recognition from the Department of Scientific and Industrial Research (DSIR), Government of India, for its R&D wing, Venus Medicine Research Centre (VMRC). This renewal confirms the company's compliance with stringent R&D standards, including qualified staffing and dedicated expenditure accounting. The recognition is pivotal for the development of VRP-034, a novel formulation that already holds a USFDA Qualified Infectious Disease Product (QIDP) designation. Such certifications are essential for pharmaceutical companies to claim tax benefits and access government research grants.
Key Highlights
Renewal of DSIR recognition for the Venus Medicine Research Centre (VMRC) unit.
Supports the development of VRP-034, which carries a USFDA QIDP designation.
Validates the company's dedicated R&D expenditure and qualified scientific infrastructure.
Facilitates ongoing research in antimicrobial resistance and the GASAR surveillance study.
👀 What to Watch
Investors should view this as a positive validation of the company's technical capabilities and R&D infrastructure. Monitor the progress of the VRP-034 pipeline as it represents a significant value driver in the antimicrobial space.
Venus Remedies FY26 Revenue Up 19% to ₹768.7 Cr; Declares ₹10 Dividend
Venus Remedies Limited reported a robust financial performance for the fiscal year ending March 31, 2026, with annual revenue from operations growing 19.3% to ₹768.73 Crores. Profit Before Tax (PBT) saw a significant surge, reaching ₹130.67 Crores compared to ₹69.15 Crores in the previous fiscal year. The company has recommended a final dividend of ₹10 per share (100% of face value), reflecting strong cash flow and profitability. Additionally, the board approved the adoption of a new MOA and AOA to align with the Companies Act 2013.
Key Highlights
Annual revenue from operations increased to ₹768.73 Crores in FY26 from ₹644.47 Crores in FY25.
Profit Before Tax (PBT) for the full year nearly doubled to ₹130.67 Crores.
Q4 FY26 revenue grew 31.6% YoY to ₹259.01 Crores compared to ₹196.74 Crores in Q4 FY25.
Recommended a final dividend of ₹10 per equity share (100% of face value) with a record date of August 7, 2026.
Board approved the adoption of new Memorandum and Articles of Association as per Companies Act 2013.
👀 What to Watch
The significant jump in profitability and the healthy dividend payout indicate strong operational momentum; investors may consider holding the stock to benefit from improved margins and yield.
Venus Remedies FY26 Revenue Up 19% to ₹769 Cr; Declares 100% Final Dividend of ₹10/Share
Venus Remedies reported a strong financial performance for FY 2025-26, with annual revenue from operations growing 19.3% YoY to ₹768.73 crore. Profit before tax (PBT) saw a massive surge, reaching ₹130.67 crore compared to ₹69.15 crore in the previous fiscal year. The company has recommended a final dividend of ₹10 per share (100% of face value), with the record date set for August 7, 2026. Operational efficiency improved significantly as Q4 FY26 PBT more than doubled year-on-year to ₹57.57 crore.
Key Highlights
Annual revenue from operations increased to ₹768.73 crore in FY26 from ₹644.47 crore in FY25.
Profit Before Tax (PBT) for the full year surged 89% YoY to ₹130.67 crore.
Q4 FY26 revenue stood at ₹259.01 crore, representing a 31.6% growth compared to ₹196.74 crore in Q4 FY25.
Declared a final dividend of ₹10 per equity share (100% of face value) for the financial year 2025-26.
Record date for dividend eligibility is August 7, 2026, with the AGM scheduled for August 20, 2026.
👀 What to Watch
Investors should view the significant jump in profitability and the 100% dividend declaration as a strong sign of operational recovery; consider holding for the dividend and monitoring margin sustainability in upcoming quarters.
Venus Remedies FY26 Net Profit Jumps 79% to ₹99.3 Cr; Announces ₹10 Dividend
Venus Remedies reported a stellar performance for FY 2025-26, with annual revenue from operations growing 19.3% to ₹768.73 crore. Net profit for the year surged by 79% to ₹99.30 crore, up from ₹55.50 crore in the previous fiscal, reflecting strong operational leverage. The company has recommended a final dividend of ₹10 per share (100% of face value) and announced the appointment of Mr. Saransh Chaudhary as a Whole Time Director.
Key Highlights
Annual Net Profit surged 79% YoY to ₹99.30 crore in FY26 compared to ₹55.50 crore in FY25.
Revenue from operations for the full year grew to ₹768.73 crore from ₹644.47 crore YoY.
Q4 FY26 Net Profit stood at ₹43.46 crore, a significant jump from ₹17.72 crore in Q4 FY25.
Board recommended a final dividend of ₹10 per equity share with a record date of August 7, 2026.
Mr. Saransh Chaudhary appointed as Whole Time Director effective May 26, 2026.
👀 What to Watch
The significant jump in profitability and healthy dividend payout are strong positive triggers; investors should monitor the sustainability of these margins in upcoming quarters.
Venus Remedies Declares ₹10 Dividend; FY26 Net Profit Surges 79% to ₹99.30 Cr
Venus Remedies has announced a final dividend of ₹10 per share (100% of face value) for FY 2025-26, with the record date set for August 7, 2026. The company reported a robust financial performance for the full year, with net profit jumping 79% to ₹99.30 crore compared to ₹55.50 crore in the previous year. Revenue from operations also saw a healthy growth of 19.3%, reaching ₹768.73 crore. The board has also approved the re-appointment of key management personnel, including the Managing Director, for a five-year term.
Key Highlights
Final dividend of ₹10 per equity share recommended for FY 2025-26.
Net Profit for FY26 surged 79% YoY to ₹99.30 crore from ₹55.50 crore.
Annual Revenue from Operations grew to ₹768.73 crore vs ₹644.47 crore in FY25.
Record date for dividend eligibility is August 7, 2026, with the AGM on August 20, 2026.
Earnings Per Share (EPS) significantly improved to ₹74.28 from ₹41.52.
👀 What to Watch
Investors should maintain their positions to benefit from the ₹10 dividend; the strong earnings growth and improved EPS signal positive momentum for the company.
Venus Remedies FY26 Net Profit Surges 79% to ₹99.3 Cr; Announces ₹10 Dividend
Venus Remedies reported a strong financial performance for FY26, with annual revenue from operations growing 19% to ₹768.73 crore. The company's net profit for the full year saw a significant jump of 79%, reaching ₹99.30 crore compared to ₹55.50 crore in the previous fiscal. In addition to the robust earnings, the board has recommended a final dividend of ₹10 per equity share (100% of face value). The company also confirmed the re-appointment of key leadership, including CEO Saransh Chaudhary, ensuring management stability.
Key Highlights
Annual Net Profit increased by 79% YoY to ₹99.30 crore for FY26
Q4 Revenue from operations grew 31.6% YoY to ₹259.01 crore
Board recommended a final dividend of ₹10 per share (100% payout on face value)
Full-year EBIDTA rose significantly to ₹155.57 crore from ₹90.77 crore in FY25
Record date for dividend eligibility is fixed as August 7, 2026
👀 What to Watch
Investors should view the strong bottom-line growth and high dividend payout as positive indicators of financial health; the stock remains a 'buy' for those looking for growth in the pharma sector with a focus on yield.
Venus Remedies Recommends Rs 10 Dividend; FY26 Net Profit Jumps 79% to Rs 99.3 Cr
Venus Remedies has recommended a final dividend of Rs. 10 per share (100%) for FY 2025-26, with a record date of August 7, 2026. The company reported a robust financial performance, with annual standalone revenue rising 19% to Rs. 768.73 Crores. Net profit for the year surged by 79% to Rs. 99.30 Crores, driven by improved margins and operational growth. The Board also confirmed the 37th AGM for August 20, 2026.
Key Highlights
Recommended a final dividend of Rs. 10 per share (100% of face value).
FY26 Standalone Net Profit grew 78.9% YoY to Rs. 99.30 Crores.
Annual Revenue from Operations increased 19.3% to Rs. 768.73 Crores.
Earnings Per Share (EPS) surged to Rs. 74.27 from Rs. 41.51 in the previous year.
Record date for dividend eligibility is set for August 7, 2026.
👀 What to Watch
The stock shows strong fundamental growth with a significant profit surge and a healthy dividend payout; investors may consider holding for long-term value.
Venus Remedies FY26 Net Profit Surges 79% to ₹99.3 Cr; Announces ₹10 Dividend
Venus Remedies reported a strong financial performance for the fiscal year ended March 31, 2026, with annual revenue growing 19% to ₹768.73 crore. Net profit for the year saw a significant jump of 79%, reaching ₹99.30 crore compared to ₹55.50 crore in the previous year. The Board has recommended a final dividend of ₹10 per equity share (100%), with the record date set for August 7, 2026. Additionally, the company re-appointed key management personnel and updated its internal and cost auditors for the upcoming fiscal year.
Key Highlights
Annual Revenue from Operations increased by 19.3% YoY to ₹768.73 crore in FY26.
Net Profit for the full year grew by 78.9% to ₹99.30 crore from ₹55.50 crore in FY25.
EBITDA for FY26 stood at ₹155.57 crore compared to ₹90.77 crore in the previous year.
Board recommended a final dividend of ₹10 per share (100% of face value) for shareholders.
Q4 FY26 revenue reached ₹259.01 crore, a 31.6% increase over the ₹196.74 crore reported in Q4 FY25.
👀 What to Watch
Investors should consider the strong bottom-line growth and the 100% dividend payout as positive indicators of the company's operational efficiency. The stock remains a solid hold/buy candidate for those looking for growth in the pharmaceutical sector with a healthy dividend yield.
Venus Remedies Q4 PAT Jumps 145% YoY to ₹43.46 Cr; Declares ₹10 Dividend
Venus Remedies reported a robust performance for Q4 FY26, with standalone revenue from operations rising 31.6% YoY to ₹259.01 crore. Net profit for the quarter surged to ₹43.46 crore from ₹17.72 crore in the previous year, driven by improved operational efficiencies. For the full fiscal year 2025-26, the company recorded a net profit of ₹99.30 crore, a significant jump from ₹55.50 crore in FY25. The board has also rewarded shareholders with a final dividend of ₹10 per share (100% of face value).
Key Highlights
Standalone Q4 Revenue from operations grew 31.6% YoY to ₹259.01 crore.
Net Profit for Q4 FY26 increased by 145% YoY to ₹43.46 crore.
Full-year FY26 EBIDTA rose to ₹155.57 crore compared to ₹90.77 crore in FY25.
Recommended a final dividend of ₹10 per equity share (100% payout) with a record date of August 7, 2026.
Full-year FY26 PAT stood at ₹99.30 crore, representing a 79% growth over the previous fiscal year.
👀 What to Watch
The strong growth in profitability and the high dividend payout signal robust financial health; investors may consider holding or accumulating on dips. Monitor the upcoming AGM on August 20, 2026, for further management commentary on expansion plans.
Venus Remedies Secures First Global Marketing Approval for Plerixafor in Saudi Arabia
Venus Remedies has received its first-ever global marketing authorization for Plerixafor from the Saudi Food and Drug Authority (SFDA). This specialty oncology injectable is used for stem cell mobilization in patients with multiple myeloma and non-Hodgkin lymphoma. The approval marks a strategic pivot for the company from commodity injectables to high-value specialty therapies in regulated markets. Saudi Arabia represents the largest pharmaceutical market in the GCC, projected to grow to USD 17.1 billion by 2033.
Key Highlights
First global Marketing Authorization for Plerixafor (24mg/1.2ml) secured from Saudi FDA
Targets the Saudi pharma market, which is projected to reach USD 17.1 billion by 2033 at a 5.0% CAGR
Addresses the GCC stem cell therapy market, estimated at USD 1.2 billion in 2024
Strategic shift toward higher-value specialty injectables to replace reliance on commodity volumes
Enables commercialization through existing international business networks and tertiary oncology centers
👀 What to Watch
Investors should monitor the revenue contribution from this high-margin specialty segment as it marks a transition in the company's product mix. The successful entry into the regulated Saudi market could serve as a precursor for further international oncology approvals.
Venus Remedies Q3 Standalone Net Profit Jumps 38% YoY to ₹24.92 Crore
Venus Remedies reported a strong standalone performance for the quarter ended December 31, 2025, with net profit rising to ₹24.92 crore from ₹18.02 crore in the previous year. Revenue from operations grew to ₹179.95 crore, supported by improved operational efficiency as EBITDA rose to ₹39.13 crore. However, auditors raised an emphasis of matter regarding the German subsidiary, Venus Pharma GmbH, which has a negative net worth of ₹94.15 lakhs. Management expects a turnaround in the subsidiary's financial position by the end of FY 2025-26 through ongoing restructuring.
Key Highlights
Standalone Net Profit increased by 38.3% YoY to ₹24.92 crore in Q3 FY26.
Revenue from operations for the quarter stood at ₹179.95 crore compared to ₹172.20 crore in Q3 FY25.
EBITDA for the quarter improved significantly to ₹39.13 crore from ₹24.65 crore in the year-ago period.
Auditors flagged a negative net worth of ₹94.15 lakhs at the German subsidiary, Venus Pharma GmbH.
Share application money of ₹2,859.72 lakhs remains pending for allotment in the German subsidiary as part of strategic restructuring.
👀 What to Watch
Investors should view the strong standalone profit growth positively but must monitor the 'Emphasis of Matter' regarding the German subsidiary's going concern status. The stock remains a watch for successful execution of the European operational restructuring by year-end.
Venus Remedies Clarifies Reporting Errors; Q2 Net Profit Rises to ₹20.13 Cr
Venus Remedies has responded to exchange clarifications regarding clerical errors in its Q2 FY26 financial filings, specifically addressing UDIN duplication and document formatting. Despite these administrative issues, the company reported a strong consolidated net profit of ₹20.13 crore for the quarter ended September 2025, up from ₹3.51 crore in the previous year. However, the auditor highlighted that the German subsidiary, Venus Pharma GmbH, has a negative net worth of ₹1.32 crore, creating material uncertainty. Management expects the subsidiary's position to stabilize by the end of FY 2025-26.
Key Highlights
Consolidated Net Profit surged to ₹20.13 crore in Q2 FY26 compared to ₹3.51 crore in Q2 FY25
Total Income for the quarter stood at ₹184.48 crore, up from ₹178.03 crore year-on-year
Company clarified that UDIN duplication in audit reports was a clerical error and re-submitted documents
German subsidiary Venus Pharma GmbH reported a negative net worth of ₹1.32 crore
Basic EPS for the quarter improved significantly to ₹15.08 from ₹2.63 in the corresponding previous quarter
👀 What to Watch
Investors should monitor the turnaround progress of the German subsidiary as its negative net worth is a point of concern. The strong quarterly profit growth is positive, and the reporting errors appear to be non-material clerical issues.
Venus Remedies Receives ₹11.78 Crore Incentive Under PLI Scheme
Venus Remedies Limited has been awarded an incentive of ₹11,77,50,000 under the Government of India's Production Linked Incentive (PLI) scheme. This marks the second disbursement for the company, which had previously received ₹10 crore under the same scheme. The total incentive received under this program now stands at approximately ₹21.78 crore. This cash inflow is expected to support the company's operational excellence and innovation in pharmaceutical manufacturing.
Key Highlights
Awarded ₹11,77,50,000 as the second disbursement under the PLI scheme
Previously received a sum of ₹10 crore under the same government initiative
Total incentives received under the PLI scheme now aggregate to ₹21.78 crore
The incentive reinforces the company's commitment to pharmaceutical manufacturing and innovation
👀 What to Watch
Investors should view this as a positive development that strengthens the company's cash position and validates its manufacturing capabilities. Monitor the impact on upcoming quarterly margins and any further updates on capacity expansion.
Venus Remedies Secures First Marketing Approval for Ceftazidime + Avibactam in Indonesia
Venus Remedies Limited has received its first marketing authorization in Indonesia for the antibiotic combination Ceftazidime + Avibactam. This product is designed to treat serious infections caused by multi-drug resistant gram-negative pathogens, such as complicated urinary tract infections. Indonesia is a major pharmaceutical market in Southeast Asia, and this approval allows the company to leverage existing distribution partnerships for commercialization. This move strengthens the company's portfolio of high-barrier-to-entry therapies in the strategically important South-East Asian region.
Key Highlights
First marketing authorization for Ceftazidime + Avibactam in the Indonesian market
Product targets serious multi-drug resistant gram-negative pathogens and urinary tract infections
Indonesia represents one of the largest pharmaceutical markets in Southeast Asia
Commercialization will be executed through existing distribution partnerships in the region
👀 What to Watch
Investors should view this as a positive expansion into a high-growth market with specialized therapies. Monitor the impact on international sales and margins in upcoming quarterly reports.
Venus Remedies Receives Final ₹11 Crore Milestone Payment from Cipla for AMR Product
Venus Remedies has successfully received the final milestone payment of ₹11 crore from Cipla Ltd, marking the completion of all commercial milestones under their 2019 licensing agreement. The patented anti-infective product, developed by Venus Medicine Research Centre (VMRC), has treated over one million patients in India to date. This payment serves as a commercial validation of the company's R&D efforts in the Antimicrobial Resistance (AMR) segment. The company is now focusing on its advanced pipeline, including candidates like VRP-034 and MET-X which have received US FDA QIDP designations.
Key Highlights
Received final ₹11 crore milestone payment from Cipla Ltd for a novel AMR-focused anti-infective.
Completion of all anticipated commercial milestones agreed upon in the 2019 licensing arrangement for India.
The product has delivered therapeutic benefits to over 1 million patients with a favorable safety profile.
Reinforces R&D pipeline strength with US FDA QIDP-designated candidates VRP-034 and MET-X.
Venus Remedies maintains a commercial presence in over 90 countries with 1,050+ marketing authorizations.
👀 What to Watch
Investors should view this as a positive validation of the company's R&D monetization strategy; focus should now shift to the clinical progress of their US FDA-designated pipeline candidates.
Venus Remedies Resolves Tax Matters, Eliminates ₹33.44 Cr Contingent Liability
Venus Remedies Limited has successfully concluded all pending Income Tax matters related to previous assessment years following favorable appellate decisions. This resolution has resulted in the complete elimination of a ₹33.44 crore contingent liability, which now stands at nil. Additionally, the company has received refunds for amounts previously deposited under protest, along with applicable interest. This development provides significant financial clarity and strengthens the company's balance sheet by removing potential future tax outflows.
Key Highlights
Complete resolution of all pending Income Tax matters for earlier assessment years.
Elimination of ₹33.44 crore in contingent liabilities, reducing the figure to nil.
Receipt of tax refunds for amounts previously deposited under protest, including interest.
Favorable decisions at the appellate level led to the issuance of final orders by tax authorities.
👀 What to Watch
Investors should view this as a positive development that improves financial transparency and provides a cash inflow through tax refunds. The removal of a significant contingent liability reduces the risk profile of the company's balance sheet.
